Glucose Teva (Glucose, Anhydrous)

Glucose Teva is a pharmaceutical‑grade anhydrous glucose produced by Teva and marketed in the European Union. The product contains glucose, anhydrous as the sole active ingredient; specific strength and dosage form are not disclosed. Classified as an excipient, it is intended for parenteral preparations administered via epidural, intrabursal, or intracoronary routes. It is supplied in a sterile container for aseptic use and may serve as an energy or osmotic agent.

Glucose Teva is used primarily as an excipient in parenteral formulations where a sterile source of carbohydrate is required.

- Provides an immediate source of glucose for cellular metabolism during procedures. - Serves as an osmotic agent to maintain fluid balance in epidural or intracoronary infusions. - Acts as a diluent or carrier for other injectable medications. - Facilitates the preparation of isotonic solutions for intrabursal injections. - Supports energy requirements in cardiac catheterization procedures.

Adverse reactions to Glucose Teva are generally related to the systemic effects of glucose when administered intravenously or via other parenteral routes.

Common: - Transient hyperglycemia. - Nausea or vomiting. - Local irritation at the injection site. - Headache. - Flushing or warmth sensation. - Mild dizziness.

Serious: - Severe hyperglycemia requiring medical intervention. - Anaphylactic or severe allergic reaction. - Electrolyte disturbances (e.g., hyponatremia). - Pulmonary edema in susceptible patients. - Seizures secondary to extreme glucose shifts. - Hypoglycemia if glucose is over‑corrected in diabetic patients.

When using Glucose Teva, clinicians should consider patient‑specific factors and monitor for potential complications.

- Assess baseline blood glucose and adjust dosing in diabetic or hypoglycemic patients. - Use caution in patients with renal or hepatic impairment due to altered glucose metabolism. - Monitor electrolytes, especially sodium and potassium, during large volume administrations. - Avoid rapid infusion rates that may cause fluid overload or osmotic shifts. - Ensure sterile technique to prevent contamination of the product. - Review patient allergy history before administration.

Glucose Teva may interact with other agents that affect blood glucose levels or fluid balance.

Avoid: - Concurrent high‑dose insulin therapy without glucose monitoring. - Co‑administration with other hyperosmolar solutions that could exacerbate fluid shifts. - Use with medications that cause severe hypoglycemia (e.g., sulfonylureas) without close monitoring.

Use with caution: - Beta‑blockers, which may mask hypoglycemia symptoms. - Diuretics that alter electrolyte status. - Corticosteroids, which can increase glucose production. - Cardiac glycosides, where fluid overload may affect cardiac function.